William Roberts, MD, a “legend in cardiovascular medicine,” died at 90 from renal cell carcinoma. Dr. Roberts was born in 1932 in Georgia and was the son of Stewart Roberts, MD, the first cardiologist in the South, according to an in memoriam piece published in the Journal of American College of Cardiology. Dr. Roberts was […]
Top of the morning to you. Gray skies are hovering over the Pharmalot campus right now, but our spirits remain sunny, nonetheless. Why? We will trot out a bit of insight from the Morning Mayor, who would say “Every new day should be unwrapped like a precious gift.” To celebrate the notion, we are brewing […]
CNN — The weight loss drug Wegovy was shown to reduce the risk of heart attack, stroke or heart disease-related death by 20% in a major clinical trial in people with cardiovascular disease, the first to show a weight loss drug alone can have such protective effects. Novo Nordisk studied Wegovy against placebo in addition […]
Bloomberg | | Posted by Zarafshan Shiraz Aug 08, 2023 04:41 PM IST Share Via Copy Link New study shows patients with obesity and with a history of cardiovascular issues taking the Novo drug were 20% less likely to suffer a cardio event Novo Nordisk A/S shares surged to a record after the Danish company’s […]
Topline The weight-loss drug Wegovy lowers the risk of “adverse cardiovascular events” by 20%, according to data from a major trial shared by the drug’s maker Novo Nordisk on Tuesday, causing the company’s shares to surge. Key Facts In a press release, Novo Nordisk said a weekly 2.4 milligram dose of semaglutide—the generic name for […]
Novo Nordisk’s semaglutide injection reduced major adverse cardiovascular events by 20% in obese or overweight patients without diabetes, further bolstering the case for more widespread use of the game-changing GLP-1. Novo Nordisk said Tuesday morning that the vast SELECT trial investigating semaglutide hit its primary endpoint: the reduction in major adverse cardiovascular events (MACE), which […]
I am dissapointed! We need it to improve investment decisions, like this: “Novo Nordisk weight loss drug cuts investors stock loss risk by 20%”Why not promote its Impulsivity reduction potential.Reduced cravings = reduction of impulsivity = more long term thinking
Companies Novo Nordisk A/S Follow Aug 8 (Reuters) – Novo Nordisk (NOVOb.CO) said on Tuesday its obesity drug Wegovy reduced the risk of a major cardiovascular event like a stroke by 20% in overweight or obese people with a history of heart disease, exceeding expectations from a key late-stage trial. COMMENTS: PETER WELFORD, EQUITY ANALYST, […]
Novo Nordisk’s obesity drug Wegovy cut the risk of major heart complications by 20% in a closely-watched trial, results that could streamline insurance coverage and spur even greater demand for the highly popular therapy. The milestone Select trial of about 17,500 patients is the first to show that an obesity medication leads to long-term cardiovascular […]
By Dominic Chopping Shares in Denmark’s Novo Nordisk rose 16% Tuesday after the company said a five-year study of its obesity drug showed it reduced the risk of major adverse cardiovascular events in overweight or obese adults by 20%. Semaglutide, which is marketed as Wegovy, appeared to have a safe and well-tolerated profile and demonstrated […]